NFE2L2 generally functions as a master negative regulator of ferroptosis, because activation of the SQSTM1–KEAP1–NFE2L2 pathway is an important homeostasis mechanism to block ferroptosis in hepatocellular carcinoma (HCC) induced by sorafenib. The gene discussed is KEAP1; the disease is hepatocellular carcinoma.